久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Intercept Pharma
Intercept Pharma
Intercept Pharma Intercept Pharma

美國Intercept Pharma
Intercept Pharmaceuticals是一家生物制藥公司,公司在開發用于治療慢性肝纖維化和代謝性疾病治療方法方面正處于臨床階段。  
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing our expertise in bile acid chemistry. Our product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions.

Our Lead Product Candidate

Our lead product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which we believe has broad liver-protective properties. We are developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. We are conducting a Phase 3 clinical trial of OCA in PBC, which we call the POISE trial, that we anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. We expect results from the trial to be available in the second half of 2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC.

We own worldwide rights to OCA outside of Japan and China, where we have exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. Patents covering the composition of matter for OCA expire in 2022, before any patent term adjustments or patent term extensions. Our current plan is to commercialize OCA in the United States and Europe ourselves for the treatment of PBC by targeting a limited and focused group of specialist physicians.

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 九九久久精品国产 | 在线观看日韩精品 | 亚洲人成网站999久久久综合 | 国产在线视频在线观看 | 欧美一区二区三区在线观看 | 99精品国产免费久久国语 | 免费观看a毛片一区二区不卡 | 国内久久 | 九九精品免视看国产成人 | 亚洲乱码中文论理电影 | 久久无码av三级 | 精品69久久久久久99 | 一区二区三区视频在线观看 | 国产欧美日本在线 | 欧美一区二区三区四区视频 | 四虎影视永久在线 | 亚洲综合一区二区 | 亚洲欧洲中文字幕 | 国产欧美综合在线观看第七页 | 亚洲国产精品免费在线观看 | 日韩精品一区二区三区四区 | 欧美成人精品高清在线播放 | 精品视频一区二区三区 | 欧美日韩1区 | 伊人一级| 欧美亚洲欧美 | 国产一区二区三区欧美 | 国产成人不卡亚洲精品91 | 成人亚洲欧美日韩在线 | 欧美日韩亚洲第一页 | 亚洲欧美国产精品第1页 | 91久久精品国产一区二区 | 国产视频一区二区在线观看 | 久久国产成人 | 亚洲欧美二区三区久本道 | 美女视频黄a视频全免费网站一区 | 久久亚洲精品国产精品婷婷 | 国产精品1区2区3区在线播放 | 国产欧美日韩高清专区手机版 | 久久99国产精一区二区三区 | 亚洲色图欧美在线 |